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Abstract
Background: Despite being the most commonly used herbal for sleep disorders, chamomile’s (Matricaria recutita)
efficacy and safety for treating chronic primary insomnia is unknown. We examined the preliminary efficacy and
safety of chamomile for improving subjective sleep and daytime symptoms in patients with chronic insomnia.
Methods: We performed a randomized, double-blind, placebo-controlled pilot trial in 34 patients aged 18-65 years
with DSM-IV primary insomnia for ≥ 6-months. Patients were randomized to 270 mg of chamomile twice daily or
placebo for 28-days. The primary outcomes were sleep diary measures. Secondary outcomes included daytime
symptoms, safety assessments, and effect size of these measures.
Results: There were no significant differences between groups in changes in sleep diary measures, including total
sleep time (TST), sleep efficiency, sleep latency, wake after sleep onset (WASO), sleep quality, and number of
awakenings. Chamomile did show modest advantage on daytime functioning, although these did not reach
statistical significance. Effect sizes were generally small to moderate (Cohen’s d ≤ 0.20 to < 0.60) with sleep latency,
night time awakenings, and Fatigue Severity Scale (FSS), having moderate effect sizes in favor of chamomile.
However, TST demonstrated a moderate effect size in favor of placebo. There were no differences in adverse
events reported by the chamomile group compared to placebo.
Conclusion: Chamomile could provide modest benefits of daytime functioning and mixed benefits on sleep diary
measures relative to placebo in adults with chronic primary insomnia. However, further studies in select insomnia
patients would be needed to investigate these conclusions.
Trial Registration: ClinicalTrials.gov Identifier NCT01286324
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Background
Chronic insomnia is a highly prevalent condition, affect-
ing more than 10% of the U.S. population and as many
as 33% of adults in primary care settings, where it most
commonly presents for initial diagnosis and treatment
[1,2]. Persistent insomnia has been linked to reduced
quality of life, increased risk for psychiatric and sub-
stance use disorders, and exacerbation of accompanying
health conditions [3-5]. Estimates also indicate that
adults with untreated insomnia incur annual healthcare
costs that are more than $1,200 higher than for adults
without insomnia [6]. Thus, chronic insomnia exacts a
substantial personal and societal burden.
Hypnotic medications, in particular benzodiazepine
receptor agonists, and cognitive-behavioral therapy are
first-line treatments for chronic insomnia [7]. Despite
their demonstrated efficacy in multiple randomized con-
trolled trials, each treatment has significant limitations.
For example, while hypnotics are readily available and
easy to administer, limited data exist on their efficacy
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and safety with chronic use, tolerance and dependence
may occur with long-term use and many patients prefer
non-medication approaches to insomnia. Cognitive-
behavioral therapy for insomnia, on the other hand, is
effective in both the short- and long-term with few
apparent side effects, but accessibility for patients with
chronic insomnia is limited.
Studies indicate that a significant proportion of people
with insomnia use non-prescription remedies to manage
sleep difficulties. In an analysis of the United 2002
National Health Interview Survey Data, 4.5% of the sam-
ple of respondents with sleep problems reported using
some form of complementary and alternative medicine
(CAM) treatment over the preceding 12 months [8].
This percentage represented more than 1.6 million
adults with sleep problems in the U.S. population.
Morin and colleagues [9] found that 15% of more than
2,000 community-dwelling adults reported using at least
one herbal/dietary product for sleep problems in the
past year, compared to 11% who reported using a sleep
prescription. Yet, rigorous clinical studies assessing the
efficacy and safety of CAM therapies for chronic insom-
nia are largely lacking.
Native to Southern and Eastern Europe and Western
Asia, chamomile flowers drunk as teas, delivered in
tablets, or applied as oils have been used as medicines
for relaxation and for promoting sleep for hundreds of
years [10]. German chamomile (Matricaria recutita) is
also one of the most popular single ingredients in herbal
teas and is the most widely used herbal product for
sleep [11]. Although its putative mechanism of action is
not entirely known, preclinical studies suggest that the
flavonoid constituent apigenin produces sedative effects
through modulation of y-aminobutryic acid (GABA)
receptors [12,13]. Chamomile is generally well tolerated;
only a limited number of case reports have documented
allergic reactions with its use [14,15]. Only two con-
trolled studies have evaluated the sedative effects of cha-
momile in humans. Kupfersztain and colleagues [16]
found that 12 weeks of an herbal extract for hot flashes
that contained chamomile alleviated sleep disturbances
and fatigue more than placebo. In another study, adults
without sleep complaints who received chamomile jelly
had higher peripheral skin temperature, higher ratings
of relaxation, and, in men, lower sleep diary ratings of
sleep onset latency, nighttime wakefulness, and morning
sleepiness more than placebo [17].
In this randomized placebo-controlled pilot study, we
evaluated the preliminary efficacy, effect size and safety
of four weeks of high-grade chamomile extract in parti-
cipants with chronic primary insomnia. We hypothe-
sized that subjective measures of sleep quality and the
daytime consequences associated with chronic insomnia
would improve more with chamomile than placebo. We
also expected that chamomile would be equally well tol-
erated to placebo.
Methods
Potentially eligible participants were identified through
phone calls and emails in response to flyers posted
throughout the community and advertisements on
Craigslist. The study took place between January 2009
and December 2010. The University of Michigan Medi-
cal School Institutional Review Board approved the
study protocol and all procedures.
Men and women aged 18 to 65 years of age who met
DSM-IV [18] criteria for primary insomnia ≥ 6 months
were eligible for screening. We limited the age of the
sample to those 18 to 65 because the incidence and
causes of insomnia are significantly different in both the
younger and older populations, thus requiring unique
studies to investigate the effect of chamomile in these
populations. We further operationalized insomnia as 7-
day sleep diary evidence of a total sleep time (TST) <
6.5 hours and sleep efficiency (SE) < 85% (total sleep
time/time in bed*100) on 3 or more nights.
Exclusion criteria included unstable chronic medical
conditions, e.g., chronic heart failure, asthma, cancer
etc.; current diagnosis of a mood or anxiety disorder, e.
g., panic disorder, anxiety, obsessive-compulsive disor-
der; lifetime history of bipolar or any psychotic disorder;
any eating or substance use disorder; evidence of
another sleep disorder, such as obstructive sleep apnea
or restless legs syndrome; women who were pregnant,
lactating, or less than six months post-partum; known
allergy or sensitivity to chamomile or members of the
ragweed family; and currently taking cyclosporine, war-
farin, or any hypnotic medication.
Interested individuals were scheduled for a screening
visit. After providing written informed consent, partici-
pants underwent a physical exam and medical history,
and provided a list of concomitant medications to rule
out medical-and substance-related causes of insomnia.
Participants also completed a 4-item screener for rest-
less legs syndrome, the Berlin Questionnaire [19] to rule
out individuals at high-risk for sleep apnea syndrome,
and the Primary Care Evaluation of Mental Disorders,
Patient Health Questionnaire (PRIME-MD) a 26-item
self-administered questionnaire, which screens for five
of the most common psychiatric disorders in primary
care: depression, anxiety, alcohol abuse/dependence,
somatoform, and eating disorders [20]. Women provided
a urine pregnancy test. Physical exam and history were
performed by nurse practitioners. However, the study’s
investigators, a physician and psychiatrist, for study elig-
ibility, evaluated all data obtained from the screening
visits. Participants with acceptable screening exams were
invited to participate in the study.
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Participants who continued to be eligible after sleep
diary screening were randomly assigned to receive, M.
recutita extract, Chamomile High Grade Extract, (Medi-
Herb, [Warwick, Australia]), 270 mg orally twice daily,
or a matching placebo. Participants were instructed to
take their study capsules between lunch and dinnertime
and the second capsule around one hour before bed.
Patients were seen at the study clinic 28 days after the
baseline visit for their day 28 visit. At the baseline and
day 28 visits participants completed their FSS,[21] Beck
Depression Inventory (BDI),[22] State Trait Anxiety
Inventory,[23] Trait Subscale (STAI-T), Insomnia Sever-
ity Index (ISI),[24] and the Pittsburgh Sleep Quality
Index (PSQI) [25].
Objectives and Outcomes
Our primary objective was to compare the effects of
four weeks of Chamomile High Grade Extract to pla-
cebo on sleep diary measures. Participants completed
sleep diaries each morning for one week prior to start-
ing the experimental agent and during the last week of
the study (days 21 to 28). The sleep diary was a daily
patient log that records bedtime, rise time, sleep onset
latency; number and duration of nighttime awakenings,
and sleep quality. Total sleep time and sleep efficiency
(total sleep time/time in bed*100) were the primary
dependent variables derived from the sleep diary,
although sleep quality, sleep onset latency, sleep effi-
ciency, number of nighttime awakenings, and wake after
sleep onset were also analyzed.
The secondary objectives included: 1) evaluation of
common daytime consequences of insomnia, including
fatigue and 2) safety and tolerability as assessed by
reports at patient visits and weekly phone or email con-
tacts during the 28-day study period. Toxicities were
graded based on National Cancer Institute Common
Toxicity Criteria version 3.0 for Adverse Events [26].
Intervention
Eligible participants were randomly assigned to receive a
chamomile extract, manufactured by MediHerb (War-
wick, Australia), 540 mg (6 tablets daily), or a matching
placebo (6 tablets daily). The dose was chosen based on
the manufacturer’s recommendations and on doses used
with chamomile extract that produced a sedative effect
in rats [13]. Each capsule contained 90 mg dry extract
of chamomile flowering tops [6:1 (v/v) extraction solvent
(ethanol 70%/30% water): flowering tops] standardized
up to 2.5 mg of (-)-a-bisabolol and ≥ 2.5 mg of apigenin
per tablet. The University of Michigan Investigational
Drug Service (UM IDS) was responsible for dispensing
all study medication. Based on high performance liquid
chromatography (HPLC) and gas chromatogram mass
spectroscopy (GC-MS) analysis conducted one year after
the start of the study, 90 mg of chamomile extract con-
tained 3.9 mg of apigenin and 1.8 mg of (-)-a-bisabolol
(Integrated Biomolecule; Tuscon, AZ). Participants were
told to take the study medication twice per day with
water and to bring all unused tablets to the final (28
day) study visit.
Randomization, Blinding and Allocation
Eligible participants were randomized equally to either
placebo or chamomile groups. The randomization code
was computer-generated by the study biostatistician.
The randomization list was then given to the research
pharmacist who was not associated with the study.
The research pharmacist dispensed the study medica-
tion, which was in packs provided by the manufac-
turer, and enclosed it in numbered boxes per the
randomization scheme. All study participants as well
as all study personnel who assessed outcomes, worked
with study data, or administered tests or question-
naires were unaware of the randomization list or treat-
ment assignment. At the final study visits participants
were also asked to indicate if they thought they had
received placebo or chamomile.
Statistical Methods and Sample Size
Baseline characteristics are reported, stratified by treat-
ment group, using means and SDs for continuous vari-
ables, and counts and percentages for categorical
variables. Balance between treatment groups on baseline
characteristics was tested using independent samples t-
tests for continuous variables and Fisher exact tests for
categorical variables.
The effects of study drug versus placebo were evalu-
ated with regression models where the dependent vari-
ables were the endpoint of interest at day 28, adjusting
for treatment group and baseline value of the variable of
interest. For categorical secondary variables, Fisher exact
tests were first performed. Between groups effect sizes,
reported as Cohen’s d, were calculated using mean
change between baseline and day 28 by group and the
pooled standard deviation of the mean change of each
treatment group. Analyses were conducted according to
the intention-to-treat principle. Data were entered into
and analysed with SPSS, Windows version 18 (SPSS,
Chicago, ILL). For all analyses, two-sided tests and a sig-
nificance level of 0.05 were used. No adjustments were
made for multiple hypotheses testing as the secondary
outcomes were viewed as hypothesis generating.
Since the effect of chamomile on sleep measures had
not been studied previously, no such information was
available to guide sample size considerations. Thus, our
goal was to determine the effect size and variability of
chamomile compared to placebo to use for future sam-
ple size calculations.
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Results
Screening, Enrolment, Withdrawals and Adherence
We screened 107 people, of whom 34 met all eligibility
criteria and were randomized, 17 to the placebo and 17
to the chamomile group. Figure 1 documents reasons
for exclusions. No participants discontinued the inter-
vention. Adherence to study medications was high with
81% of all participants taking greater than 83% of all
study medication. Mean intake of tablets was 93% with
no significant differences between groups (p = 0.27).
Sociodemographic Characteristics
In Table 1, we present the sociodemographic and clini-
cal characteristics of participants by treatment group.
There were no significant differences between treatment
groups for any demographic characteristics.
Subjective Measures of Sleep
In Table 2, we present baseline and 28-day values for
each subjective sleep measure stratified by group. There
were no significant group effects for the primary
outcomes, SE% (p = 0.76) or TST (p = 0.11), nor for
any of the other sleep diary variables: sleep latency,
wake after sleep onset (WASO), number of night time
awakenings, and sleep quality. Sleep latency and number
of night-time awakenings have moderate effect sizes in
favor of chamomile. Chamomile decreased sleep latency
by approximately 16 minutes while it was increased by
around 1 minute in the placebo group. For number of
night time awakenings the placebo group decreased
awakenings by 0.3 compared to a 0.8 decrease of night
time awakenings in the chamomile group. However, the
other sleep outcome with a moderate effect size, TST
(0.59 Cohen’s d) favors the placebo group. The placebo
group saw an average increase of 0.8 hours compared to
the chamomile group, which increased by 0.2 hours in
sleep time between baseline and day 28. Other sleep
measures including sleep quality, SE% and WASO
demonstrated only small effect sizes (0.06 to 0.23
Cohen’s d).
Similarly, there were no significant group effects for
changes in the Insomnia Severity Index (ISI) (p = 0.44)
or the Pittsburgh Sleep Quality Index (PSQI) total score
(p = 0.79). Effect size for each outcome is also presented
in Table 1. Both measures favored chamomile compared
to placebo, but revealed only small effect sizes in cha-
momile’s favor.
Assessment of Daytime Consequences of Insomnia
Table 2 presents the results for daytime symptom end-
points. While not statistically significant, we did, how-
ever, see a trend in favor of chamomile (p = 0.11) for
the FSS. This resulted from a small increase in the fati-
gue scale in the placebo group (1.4 points or 2.2%
increase) and an equally small drop in the fatigue scale
in the chamomile group (4.2 points or 6.7% decrease).
The difference in the fatigue severity scale represents a
moderate effect size of 0.55.
Chamomile had no significant effect on differences in
either the BDI (p = 0.60) or the trait subscale of the
STAI (p = 0.45). However, the Trait subscale increased
by 3.3 points in the placebo group compared to decreas-
ing 0.8 points in the chamomile group representing a
moderate effect size of 0.57 favoring chamomile.
Adverse Events
Adverse events are displayed in Table 3. There were no
significant differences in total adverse events (AE)
between treatment groups with 10 AE’s reported for the
placebo group and 6 in the placebo group (p = 0.30).
All adverse events were mild (graded as a 1 on the NCI
toxicity criteria) and transient. We divided adverse
events into categories that most commonly occurred in
the trial. There were no statistically significant differ-
ences between groups for any of the adverse event
107 Assessed for Eligibility
73 Excluded:
16 Risk for Sleep Apnea
15 Mood/Personality  
Disorder
5 Chronic Pain
8 No Insomnia
2 Prohibited Medication
3 Unstable Medical 
Condition
4 Ineligible (Other reason)
20 Declined Participation
34 Randomized
17 Assigned to Chamomile 17 Assigned to Placebo
17 Analyzed to Chamomile
None lost to follow-up or 
excluded from analysis
17 Analyzed to Placebo
None lost to follow-up or 
excluded from analysis
Figure 1 Participant Flow Through the Study.
Table 1 Baseline Characteristics of the Randomization
Groups
Characteristics Chamomile
N = 17
Placebo
N = 17
Sex, No. (%)
Men 5 (29) 4 (23)
Women 12 (71) 13 (77)
Race, No. (%)
White 14 (82) 12 (71)
Age, mean (SD), years 42.2 (13.5) 40.8 (15.3)
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categories including headache (p = 0.76), dizziness (p =
1.00), infections (p = 1.00), gastrointestinal symptoms (p
= 0.66) or musculoskeletal complaints (p = 0.76).
Blinding
We found that study participants were blinded to study
assignment. Around 38% of participants believed that
they had received chamomile, 32% thought they had
received placebo and 29% reported not knowing which
treatment they received. There was no significant differ-
ence in blinding between treatment groups (p = 0.75).
Discussion
We found no benefit of a chamomile extract, in the
dose and formulation used, on our primary endpoints
of subjective sleep efficiency and total sleep time in
people with chronic primary insomnia in this preli-
minary study. We did, however, find a modest benefit
of chamomile compared to placebo on other sleep
diary measures including sleep latency (0.47 Cohen’s
d), and night time awakenings (0.61 Cohen ’s d),
although these did not reach statistical significance.
These measures of sleep quality are only slightly smal-
ler than those observed for other drug treatments for
chronic insomnia where pooled effect sizes for sleep
diary measures (e.g., sleep latency, sleep quality, and
wake after sleep onset) ranged from a mean of 0.38 to
0.79 [27].
We observed that those in the chamomile group had a
mean decreased sleep latency of a bit more than15 min-
utes, around 1/3 less night time awakening, and almost
a 7% (4.2 point decrease) reduction in the FSS compared
to placebo at day 28. These modest changes in sleep
latency and night time awakenings are comparable with
benzodiazepines, non-benzodiazepines and anti-depres-
sants [27,28]. Where weighted mean differences for
decreasing sleep onset latency range from 7.0 to 19.6
minutes depending on the drug studied and how sleep
latency was measured [27]. This is despite our study
patients, on average, experiencing milder insomnia than
those recruited in other drug studies and thus, possibly
attenuating our results due to having a less severely
affected patient sample.
Table 2 Sleep Diary and Daytime Function Measures by Treatment Group
Placebo
N = 17
Mean ± SD
Chamomile
N = 17
Mean ± SD
Measure Baseline Week 4 Baseline Week 4 Effect Sizea P-valueb
Subjective Sleep Measures
Sleep Latency (min) 33.9 ± 32.2 32.9 ± 4.3 50.3 ± 53.0 34.2 ± 6.6 0.47 0.41
Wake After Sleep Onset (min) 44.6 ± 46.3 25.9 ± 24.4 49.0 ± 36.6 32.0 ± 27.3 0.06 0.51
Awakenings (#) 1.6 ± 1.1 1.3 ± 0.7 2.2 ± 1.3 1.4 ± 0.6 0.61 0.46
Total Sleep Time (hrs) 5.8 ± 1.0 6.5 ± 1.0 5.9 ± 1.7 6.1 ± 1.2 0.59 0.07
Sleep Qualityc 3.0 ± 0.7 3.3 ± 0.5 2.7 ± 0.7 3.1 ± 0.5 0.23 0.86
Sleep Efficiency (%) 76.7 ± 12.0 83.3 ± 7.7 71.9 ± 16.7 77.5 ± 12.9 0.09 0.21
ISI Scored 13.9 ± 3.6 11.6 ± 4.5 15.1 ± 3.7 11.9 ± 4.7 0.28 0.60
PSQI Total Scored 9.5 ± 2.1 7.1 ± 2.7 10.1 ± 2.5 7.5 ± 3.3 0.10 0.88
Daytime Functioning Measures
FSSd 30.9 ± 9.1 32.3 ± 10.0 32.1 ± 10.6 27.9 ± 9.3 0.55 0.11
BDId 6.0 ± 6.0 4.8 ± 5.0 3.2 ± 1.6 2.4 ± 2.4 0.31 0.60
STAI
Trait Subscaled 37.5 ± 11.3 40.8 ± 15.5 36.3 ± 10.1 35.5 ± 11.0 0.57 0.45
aEffect size is calculated using Cohen’s d
bP-value is derived from a general linear model adjusted for group assignment and baseline value of measure
cSleep quality rated from 1 (very poor) to 5 (very good)
d BDI = Beck Depression Inventory, a score of ≥ 14 is consistent with mild depression, a score of ≥ 20 is consistent with moderate depression and a score ≥ 29
indicates severe depression; ISS = Insomnia Severity Index, 0-7 no clinically significant insomnia, 8-14 is subthreshold insomnia, 15-21 moderate clinical insomnia
and ≥ 22 severe clinical insomnia; PSQI = Pittsburgh Sleep Quality Index, scores range from 0-21 with ≥ 6 suggests poor sleep quality; STAI = State Trait Anxiety
Inventory, scores range from 20 (no to mild anxiety) to 80 (severe anxiety); FSS = Fatigue Severity Scale, scores range from 9-59 with a score of ≥ 36 indicating
significant fatigue and impairment in daytime functioning.
Table 3 Adverse Events By Person (AE’s)
Placebo N(%) Chamomile N(%) P-valuea
Any AE 10 (58.8) 6 (35.5) 0.03
Infections 3 (17.6) 2 (11.8) 1.00
Headaches 1 (5.9) 1 (5.9) 0.76
Dizziness 1 (5.9) 0 (0.0) 1.00
GI Symptoms 4 (23.5) 2 (11.8) 0.66
Musculoskeletal 2 (11.8) 1 (5.9) 0.76
aBased on Fisher’s Exact Test
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Despite the popularity of chamomile as a sleep aid
[11] there are no published studies examining chamo-
mile for primary insomnia or for any type of chronic
sleep disorder. Two other clinical studies have examined
the sedative effect of chamomile as a secondary outcome
in healthy volunteers and in women with menopausal
symptoms [16,17]. Somewhat similar to our results, both
of these studies demonstrated that chamomile had posi-
tive effects on subjective sleep measures and in the case
of menopausal women experiencing hot flashes
improvements in fatigue as well. In contrast to our
study, which found a mixed effect of chamomile on
sleep measures, these studies both reported universally
positive effects of chamomile on sleep parameters. How-
ever, sleep disturbances in menopausal women experien-
cing hot flashes may be caused by distinctly different
mechanisms than those involved in primary insomnia.
Also, it is unclear what improvements in sleep measures
indicate in healthy volunteers without sleep
disturbances.
Chamomile extract has also been investigated for
treatment of stress and generalized anxiety disorders
(GAD). Two small studies have evaluated the effect of
chamomile essential oil on the autonomic nervous sys-
tem. Masago and colleagues found that chamomile oil
increased comfortable feelings and decreased alpha 1 (8-
10 Hz) recordings of the EEG at the parietal and tem-
poral brain regions [29]. Chamomile oil versus placebo
oil was also able to significantly shift negative mood
images and frequency judgments in a positive direction
after being asked to visualize positive or negative
phrases [30]. A RCT in people with mild to moderate
GAD found that a chamomile extract was significantly
better than a placebo extract at decreasing anxiety and
showed a positive change in favor of chamomile for
changes on the Psychological Well Being and Clinical
Global Impression Severity Score [31]. These studies
indicate that chamomile may have mild anxiolytic activ-
ity, accounting for one mechanism by which it is an
effective sleep aid. In our study, we purposely excluded
individuals who had diagnoses of depression or anxiety
in order to strictly evaluate the effect of chamomile on
chronic primary insomnia. As such, we may have
excluded the population most likely to experience sleep
benefits from chamomile, i.e., those with insomnia that
is related to an underlying anxiety disorder.
It is possible that our modest and mixed results were
due to an adequate or incorrect; dose, dosing schedule
or formulation of chamomile. There has been no dose
finding studies with any chamomile product. Conse-
quently, we based our dose on manufacturer recommen-
dations and on doses of apigenin (chamomile’s main
flavonoid constituent), which produced sedative effects
in animal models [12,13,32-34]. Even if a higher dose of
apigenin were found to improve sleep, it is not clear
that it would be practical to deliver it using chamomile.
In our current study our chamomile extract represented
15 gm of chamomile flowers/day. This amount could
not feasibly be delivered as a tea and could only be
achieved using a concentrated extract. Also, no studies
have examined the pharmacokinetics or pharmacody-
namics of chamomile, thus severely limiting the data of
when and how often chamomile should be administered.
Participants in our study took their tablets twice daily.
Perhaps more frequent dosing or administration of cha-
momile through routes other than oral administration
could yield better results. While pharmacokinetic studies
of chamomile are lacking, other studies indicate that
apigenin is orally available and has a reasonable half-life
to justify twice daily dosing in humans when delivered
in parsley (another rich source of apigenin) [35-37].
Also, it may take longer than four weeks to see larger
and more consistent effects of chamomile on sleep and
fatigue measures. For instance, the study that found an
effect in menopausal women was a 12-week RCT,[16]
although if positive effects take longer than one month
many insomnia sufferers are likely to abandon the treat-
ment. Moreover, the formulation could have been incor-
rect. For instance, drinking chamomile as a hot tea, or
inhaling it as an essential could produce better results
for improving sleep measures. Indeed, the other two stu-
dies that found a positive effect of chamomile on sleep
measures used different formulations, a chamomile jelly
and a tablet, combining chamomile with another herb
Angelica sinensis.
Chamomile appeared to be well tolerated. There was
no difference between placebo and chamomile for all
adverse events, for common AE categories including
gastrointestinal complaints. No serious adverse events
were reported and all non-serious adverse events were
mild and transient in nature. Also, our participants were
highly adherent taking more than 93% of their tablets
on average, indicating that chamomile tablets are both
safe and acceptable as a treatment.
Our study had several limitations. First, we were lim-
ited by the use of subjective, i.e., pen and pencil, sleep
measures. Objective measures of sleep, such as actigra-
phy or polysomnography, would have been valuable to
include and should be used in future studies. Second,
we did not assess the characteristics of participants’
sleep difficulties, i.e., initial, middle, late or early morn-
ing, mixed or non-restorative sleep. These differences in
when participants are experiencing sleep issues may be
important considering the age-range of individuals
included in the study (20-65 years old) and thus, it
could be possible that chamomile extract might be more
effective for one type or another of sleep difficulties. We
were unable to examine these differences in timing due
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our small sample size with only a few if any participants
in any given time category. Also, this was a pilot study
and thus we had a small sample size of only 34 partici-
pants. However, it was our intention to determine the
effect size, direction of effect, and clinical relevance of
chamomile on sleep and fatigue outcomes not necessa-
rily statistical significance. Thus, our small number of
participants was able to give a good indication of which
sleep and fatigue parameters chamomile may benefit
and guide future clinical trials in chronic insomnia suf-
ferers. Also, we were able to generate data to determine
how many participants would be needed to detect statis-
tically significance differences. For instance, to detect a
statistically significant difference in the sleep diary vari-
able with the smallest effect size (0.06 for WASO), a
total sample size of 2175 would be required, while only
60 participants (30 per group) would be necessary to
detect a significant difference in sleep onset latency
(effect size of 0.47).
Conclusion
In summary, the data from this study points towards the
possibility that chamomile extract could provide modest
and mixed clinical benefit, at the doses evaluated, to
patients with chronic primary insomnia. It is possible,
however, that the improvements in the chamomile
group are due to events unrelated to treatment, such as
natural course of illness and regression toward the
mean. Future small studies with chamomile may be war-
ranted in patients with more severe insomnia; those
patients whose main insomnia complaints are sleep
onset latency or large number of night time awakenings;
or patients for whom the side-effects of current insom-
nia medications are contraindicated or problematic.
Also, as chamomile appears beneficial for mild to mod-
erate GAD patients, pilot studies with patients diag-
nosed with insomnia comorbid with anxiety disorders
may be warranted.
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